<DOC>
	<DOC>NCT00828594</DOC>
	<brief_summary>Phase 1 Evaluate the safety and tolerability of RAD001 in combination with sorafenib in patients with advance hepatocellular cancer (HCC) and to determine the maximum tolerated dose (MTD) Phase 2 To estimate the treatment effect as a measure of anti-tumor activity in terms of Time to Progression (TTP) of the combination of RAD001 plus sorafenib, at the MTD, as compared to sorafenib alone</brief_summary>
	<brief_title>Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Advanced liver cancer No previous systemic therapy for liver cancer Measurable disease on CT or MRI ECOG 1 or less ChildPugh A Active bleeding during the last 30 days Known history of HIV seropositivity Any severe and/or uncontrolled medical conditions including Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>dose-finding study</keyword>
	<keyword>randomized trial</keyword>
	<keyword>medical treatment</keyword>
	<keyword>RAD001</keyword>
	<keyword>sorafenib</keyword>
	<keyword>Advanced hepatocellular cancer (HCC)</keyword>
</DOC>